Statement on Inadvertent Abstract Disclosure for Oveporexton (TAK-861) by World Sleep Congress
Statement on Inadvertent Abstract Disclosure for Oveporexton (TAK-861) by World Sleep Congress
July 31, 2025
An embargoed version of an abstract for our Phase 3 TAK-861-3002 study (RadiantLight) of oveporexton (TAK-861) in narcolepsy type 1, which is slated to be presented at the upcoming World Sleep 2025 congress in September, was inadvertently published by the World Sleep Congress on their website. In the spirit of transparency, we are providing the abstract that was inadvertently published. Please see here for more details.